Source: Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Olle-Monge, D. Alvarez-Simón, S. Gómez-Ollés, M. D. Untoria, F. Morell, M. J. Cruz, X. Munoz (Barcelona, Spain). Persistence of the asthmatic response in two animal models with exposure to high and low molecular weight agents. Eur Respir J 2013; 42: Suppl. 57, 4247

Member's Comments

No comment yet.

Related content which might interest you: Occupational asthma induced by exposure to high and low molecular weight agents. Similarities and differences Source: Annual Congress 2013 –Occupational respiratory diseases: asthma, silicosis and asbestosis Year: 2013 Anti-IgE as an alternative treatment for occupational asthma due to low molecular weight agents Source: International Congress 2016 – Occupational and environmental exposures and biomarkers: human studies, animal data, and in vitro methods Year: 2016 A murine ovalbumin model exhibits molecular features of steroid insensitive human asthma Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 A new naturalistic asthma model in the environmental exposure chamber to study mild asthmatics safely and consistently Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Effects of prenatal tobacco smoke exposure on pulmonary signaling networks in a murine model Source: International Congress 2014 – Mechanistic murine studies of asthma and lung inflammation Year: 2014 Crucial timing of a viral component exposure to exacerbate allergen-induced asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 TH2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 The effect of different PV extracts in the treatment of asthma in an animal model Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Differences in association between endotoxin and asthma and wheeze with environmental exposures Source: International Congress 2015 – Indoor air and ambient pollution Year: 2015 Effects of chronic cigarette smoke exposure on lung inflammation in ovalbumin-sensitized mice Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Dose-dependent differential effects of thrombin in allergic bronchial asthma Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 Environmental tobacco smoke (ETS) induced immunologic changes in children with asthma Source: International Congress 2014 – Paediatric asthma: epidemiology and risk factors Year: 2014 Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 Standardization of a murine model of asthma due to soybean inhalation Source: International Congress 2015 – Occupational and environmental effects: in vitro and animal models Year: 2015 Higher prevalence and level of IgE, particularly to furry animals, in subjects with asthma in Sweden Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 B cells in a murine model of allergic asthma and respiratory tolerance Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Obese patients with partially controlled asthma: Weight control shows more benefit in IgE low patients Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Duvelisib, a PI3K-δ,γ inhibitor, in subjects with mild asthma Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015